# Bleeding Time Study With AZD6482, Clopidogrel and ASA

> **NCT00853450** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 28 (estimated)

## Conditions studied

- Antiplatelet Effect

## Interventions

- **DRUG:** AZD6482
- **DRUG:** Clopidogrel
- **DRUG:** ASA

## Key facts

- **NCT ID:** NCT00853450
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** —
- **Final completion:** 2009-07
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2009-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853450, "Bleeding Time Study With AZD6482, Clopidogrel and ASA". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00853450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*